Glaxo Agrees to Pay $3 Billion in Fraud Settlement
July 3, 2012 | In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline has agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs. New York Times
